Effect of ecdysterone on glucose metabolism in vitro

Effect of ecdysterone on glucose metabolism in vitro
复制标题

DOI:
10.1016/j.lfs.2005.06.031
复制
发表时间:
2006-02-02
期刊:
影响因子:
6.1
通讯作者:
Qiu, ZY
Qiu, ZY
中科院分区:
医学2区
文献类型:
--
作者:
Chen, Q;Xia, YP;Qiu, ZY

文献摘要

被引文献

相似文献

本研究的目的是探讨蜕皮甾酮是否能对肝细胞产生降糖作用或刺激胰岛素分泌。HepG 2细胞系用于葡萄糖消耗(GC)研究。在中度高糖浓度(11.1 mmol/L)下,蜕皮甾酮1 × 10(-6)~ 1 × 10(-4)mol/L可使HepG 2细胞的GC增加44%~ 77%,与1 × 10(-3)mol/L二甲双胍相当。蜕皮甾酮的降糖作用随培养基中葡萄糖浓度的增加而减弱。当葡萄糖浓度为5.5mmol/L时,该效应最大,当葡萄糖浓度增加到22.2mmol/L时,该效应消失。这种作用与胰岛素浓度无关,与二甲双胍相似,与曲格列酮不同,曲格列酮的降糖作用是胰岛素依赖性的。当加入胰岛素时,曲格列酮的降糖效力优于二甲双胍。同时,曲格列酮对HepG 2细胞有明显的毒性作用。β TC 3细胞不受蜕皮甾酮刺激,即没有观察到蜕皮甾酮的促分泌作用。结果表明,蜕皮甾酮对胰岛素依赖的肝细胞具有降糖作用,但对胰岛素的释放无影响。(c)2005年爱思唯尔公司All rights reserved.
The aims of this study was to investigate whether ecdysterone is able to exert glucose-lowering effect on hepatocytes or stimulate the secretion of insulin. HepG2 cell line was used for glucose consumption (GC) studies. At moderate high glucose concentration (11.1 mmol/L), GC of HepG2 cells was increased by 44% to 77% with ecdysterone 1 x 10(-6) to 1 x 10(-4) mol/L, which was comparable to that with 1 x 10(-3) mol/L metformin. The glucose-lowering effect of ecdysterone decreased as the glucose concentration of medium increased. The maximal potency was reached in the presence of 5.5 mmol/L glucose, and the effect was disappeared as the glucose consumption was increased to 22.2 mmol/L. This effect was independent on insulin concentration, which was similar to that of metformin and was different from that of troglitazone, whose glucose-lowering effect was insulin-dependent. Troglitazone had a better antihyperglycemic potency than metformin when insulin was added. Simultaneously, a significant toxicity of troglitazone to HepG2 cells was observed. beta TC3 cells were not stimulated by ecdysterone, that is, no secretogogue effect of ecdysterone was observed. The results indicate that ecdysterone is able to exert the glucose-lowering effect in hepatocytes which is insulinin-dependent, but has no effect on insulin release. (c) 2005 Elsevier Inc. All rights reserved.